Anocca AB

https://www.anocca.com

Anocca is leveraging its highly scalable precision analysis technologies to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. The company’s innovative ‘engineered immunity’ approach to deciphering T cell immunity can reach an unprecedented number of druggable targets in oncology and other therapeutic areas, such as infectious diseases and autoimmune disorders. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company’s platform has generated a broad pipeline of blockbuster assets focusing on distinct disease franchises. The company expects to progress several TCR-T therapies to the clinic. Anocca was founded in 2014 and is led by an experienced management team that has raised over USD 100 million in funding from leading Nordic investors Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco and Michano with Danske Bank acting as advisor. Anocca’s team of over 65 employees operates from its site in Södertälje, Sweden. *

	Start	2014-01-01 established
	Industry	immunotherapy

	Region	Södertälje
	Country	Sweden
	Street	20C Forskargatan
	City	15136 Södertälje
		Address record changed: 2021-07-26

Basic data	Employees	C: 51 to 100 (2021-07-22)

		* Document for »About Section«: Anocca AB. (7/22/21). "Press Release: Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy". Södertälje.

		Record changed: 2024-02-12

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Anocca AB

[1] Anocca AB. (7/22/21). "Press Release: Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy". Södertälje....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)